Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Nov 14.

Published in final edited form as: Int J Infect Dis. 2022 Jul 16;122:785–792. doi: 10.1016/j.ijid.2022.07.035

Table 1.

Baseline characteristics by CMV viremia status

	CMV viremia present	CMV viremia absent	P-Value^a
N per group	121	219
Women	52 (43%)	81 (37%)	0.28
Age, years	35 [29–40]	35 [30–40]	0.63
CD4⁺ T-cell count per μl	14 [6–53]	24 [8–61]	0.07
CD4:CD8 ratio	0.1 [0.0–0.1]	0.1 [0.0–0.1]	0.73
Receiving ART	57 (47%)	98 (45%)	0.68
Months on ART	2.5 [0.5–20]	3.8 [1.1–32]	0.22
CMV DNA, IU/ml	452 [142–2450]	0 [0–0]
Glasgow Coma Scale score <15	49 (41%)	88 (40%)	0.95
Hemoglobin, g/dl	11.0 [9.5–12.6]	11.6 [10.3–13.0]	0.01
CSF white cells ≤5 cells/μl	85 (73%)	126 (60%)	0.03
CSF opening pressure, mmH₂ 0	260 [180–370]	270 [170–410]	0.52
Randomized to Intervention	76 (63%)	151 (69%)	0.07
Meningitis			0.59
Cryptococcal meningitis (N = 308)	111 (36%)	197 (64%)
TB meningitis (N = 32)	10 (31%)	22 (69%)

Data are N (%) or median [interquartile range].

^a

P-values are from chi-square or Kruskal-Wallis testing.ART, antiretroviral therapy; mmH₂ 0, millimeters of water.